J&J agrees to buy Firefly Bio for $1 billion in cash to expand KRAS-focused oncology pipeline

Johnson & Johnson agreed to acquire Firefly Bio for $1 billion in cash, adding the Firelink degrader antibody conjugate platform to its oncology pipeline. The platform is aimed at KRAS-driven solid tumors, where patients have limited options. The deal was expected to close later in 2026, subject to regulatory approvals and customary conditions.

• Price: $1 billion in cash
• Target platform: Firelink degrader antibody conjugate (DAC) technology
• Focus: KRAS-driven solid tumors
• Expected to close later in 2026, subject to regulatory approvals